* Intercell to get upfront, option and milestone payments
* Will also get royalties on product net sales
* Boehringer to use certain antigens from Intercell's AIP
(Adds detail, background)
ZURICH, May 10 Austrian biotech company
Intercell ICEL.VI and German gorp Boehringer Ingelheim
Vetmedica have struck a deal to develop animal vaccines, marking
Intercell's first move outside human health.
Intercell, which is developing vaccines for a number of
infectious diseases, will get upfront, option and milestone
payments as well as royalties on product sales, it said on
Boehringer Ingelheim Vetmedica will have the right to use
certain antigens from Intercell's antigen identification
programme (API) to develop animal vaccines, Intercell said.
Intercell, the only major independent vaccine maker left in
Europe aside from Dutch company Crucell CRCL.AS, last year
started to sell its Japanese Encephalitis vaccine Ixiaro,
distributed with Swiss group Novartis NOVN.VX.
The group is also developing a vaccine for S.aureus, a type
of bacteria that can cause serious infection, with Merck KGaA
(MRCG.DE) and a vaccine patch against traveller's diarrhea,
which it is developing with GlaxoSmithKline (GSK.L).
(Reporting by Katie Reid; Editing by Dan Lalor)